On 7 March 2022, XtalPi, an industry-leading AI pharmaceutical company, made the list of “Fierce 15” as one of the most promising pharmaceutical technology companies in 2021. The list was published by Fierce Medtech, a well-known biotech media organization in the United States. It is the first time for a Chinese company to win such an award in recent years.
In 2021, XtalPi achieved comprehensive and multi-fold growth. In particular, it realized tens-fold growth in AI new drug discovery business and achieved landmark progress in multiple R&D pipelines, the clients of which are preparing for clinical trials. Currently, XtalPi is serving more than 100 global pharmaceutical and biotech companies and research institutions; at the same time, centering on its key upstream and downstream industry chains and technologies, XtalPi has incubated and invested in a number of innovative companies including METiS Pharmaceuticals, Signet Therapeutics, PhoreMost and Leman Biotech. With XtalPi as the core, these companies have formed a complementary and mutually empowering industrial ecosystem.
Disclaimer
Investment Involves risk. Past performance does not represent future performance. Investor should read the product’s Prospectus for details and risk factors before making investment decision. The contents of this website is prepared and maintained by Mirae Asset Capital (China) Limited. This material has not been reviewed by the Securities and Futures Commission.
Dec 13, 2024
